Regulation of pathogenic IL-17 responses in collagen-induced arthritis: Roles of endogenous interferon-gamma and IL-4

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Sarkar, Sujata ^a   Cooney, Laura A ^b   White, Peter ^b   Dunlop, Deborah B ^a   Endres, Judith ^b   Jorns, Julie M ^c   Wasco, Matthew J ^c   Fox, David A ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FREUND ADJUVANT; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE INJURY; CARTILAGE INJURY; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOREFOOT; HISTOLOGY; LYMPH NODE; LYMPHOID ORGAN; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SPLEEN; SUPERNATANT; ANIMAL; CELL SEPARATION; DBA MOUSE; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; MALE; MICE; MICE, INBRED DBA; T-LYMPHOCYTE SUBSETS;

EID: 75649140602     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2838     Document Type: Article

References (47)

1. Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol 2004, 31:2336-2346.
2. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352. 408356, 10225978, 10.1172/JCI5703.
3. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
4. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603. 2192621, 8676080, 10.1084/jem.183.6.2593.
5. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309. 10.1038/46303, 10580503.
6. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44:1293-1303. 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T, 11407688.
7. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131. 10.1002/art.21749, 16572447.
8. Lubberts E, Joosten LA, Oppers B, Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, Loo FA, Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
9. Lubberts E, Koenders MI, Oppers-Walgreen B, Bersselaar L, Coenen-de Roo CJ, Joosten LA, Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659. 10.1002/art.20001, 14872510.
10. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
11. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
12. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. 1618871, 16200068, 10.1038/ni1261.
13. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier MC, Fournier C. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501-5506.
14. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
15. Mauritz NJ, Holmdahl R, Jonsson R, Meide PH, Scheynius A, Klareskog L. Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988, 31:1297-1304. 10.1002/art.1780311012, 3140821.
16. Cooper SM, Sriram S, Ranges GE. Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. J Immunol 1988, 141:1958-1962.
17. Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999, 163:5383-5390.
18. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 2008, 181:329-337. 2495052, 18566398.
19. Boissier MC, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, Fournier C. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995, 25:1184-1190. 10.1002/eji.1830250508, 7774621.
20. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999, 1:81-91. 17779, 11056663, 10.1186/ar14.
21. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, Mule JJ, McDonagh KT, Fox DA. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001, 107:1275-1284. 209294, 11375417, 10.1172/JCI11490.
22. Lubberts E, Joosten LA, Chabaud M, Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, Berg WB. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710. 378501, 10862785, 10.1172/JCI7739.
23. Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 2007, 56:89-100. 10.1002/art.22311, 17195211.
24. Ortmann RA, Shevach EM. Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 2001, 98:109-118. 10.1006/clim.2000.4961, 11141333.
25. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145-1151. 10.1002/art.22453, 17393396.
26. Irmler IM, Gajda M, Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 2007, 179:6228-6236.
27. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, Nakamura T, Shimizu M, Kawabata D, Yukawa N, Hashimoto M, Sakaguchi N, Sakaguchi S, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Mimori T. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 2009, 60:2294-2303. 10.1002/art.24687, 19644886.
28. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974. 10.1038/ni1488, 17581537.
29. Ohmura K, Nguyen LT, Locksley RM, Mathis D, Benoist C. Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum 2005, 52:1866-1875. 10.1002/art.21104, 15934072.
30. Nandakumar KS, Holmdahl R. Arthritis induced with cartilage-specific antibodiesis IL-4-dependent. Eur J Immunol 2006, 36:1608-1618. 10.1002/eji.200535633, 16688680.
31. Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol 2002, 102:185-191. 10.1006/clim.2001.5162, 11846461.
32. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40:249-260. 10.1002/art.1780400209, 9041936.
33. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397. 10.1038/ni1539, 17994024.
34. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3:811-821. 10.1016/1074-7613(95)90070-5, 8777726.
35. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
36. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
37. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000, 12:1092-1099. 10.1006/cyto.2000.0681, 10880256.
38. Rifas L, Arackal S. T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthritis Rheum 2003, 48:993-1001. 10.1002/art.10872, 12687541.
39. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483. 10.1038/nature05969, 17581589.
40. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234. 10.1038/nature04754, 16648837.
41. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
42. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651. 10.1038/nature05505, 17187052.
43. Woods JM, Amin MA, Katschke KJ, Volin MV, Ruth JH, Connors MA, Woodruff DC, Kurata H, Arai K, Haines GK, Kumar P, Koch AE. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 2002, 13:381-393. 10.1089/10430340252792512, 11860705.
44. Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Haines GK, Kumar P, Koch AE. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001, 166:1214-1222.
45. Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. Biochem Biophys Res Commun 2005, 329:839-845. 10.1016/j.bbrc.2005.02.049, 15752732.
46. Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, Mikecz K, Glant TT. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008, 58:2397-2408. 10.1002/art.23653, 18668542.
47. Prots I, Skapenko A, Wendler J, Mattyasovszky S, Yone CL, Spriewald B, Burkhardt H, Rau R, Kalden JR, Lipsky PE, Schulze-Koops H. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006, 54:1491-1500. 10.1002/art.21832, 16646030.